Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Diabetes Care

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIACARE.23.1.88PMID 10857975
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).

  1999cited by this paper
• Proinsulin, Intact Insulin, and Fibrinolytic Variables and Fibrinogen in Healthy Subjects: A population study

  1997cited by this paper
• Increased prothrombin fragment 1+2 and D-dimer in first-degree relatives of type 2 diabetic patients

  1996cited by this paper
• Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus.

  1996cited by this paper
• Hyperinsulinemia as an independent risk factor for ischemic heart disease.

  1996cited by this paper
• Fibrinolytic activity and clotting factors in ischaemic heart disease in women

  1996cited by this paper
• Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.

  1994cited by this paper
• Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study.

  1994cited by this paper
• How good a marker is insulin level for insulin resistance?

  1993cited by this paper
• Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study.

  1993cited by this paper
• Prospective analysis of the insulin-resistance syndrome (syndrome X).

  1992cited by this paper
• No Evidence for Short-Term Regulation of Plasminogen Activator Inhibitor Activity by Insulin in Man

  1992cited by this paper
• Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study.

  1992cited by this paper
• Changes in Blood Coagulation, Platelet Function, and Plasminogen-Plasmin System in Diabetes

  1992cited by this paper
• The Acute Effect of Insulin on Tissue Plasminogen Activator and Plasminogen Activator Inhibitor in Man

  1991cited by this paper
• Interrelations between carbohydrates, lipids, and the hemostatic system in relation to the risk of thrombotic and cardiovascular disease.

  1990cited by this paper
• Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man.

  1990cited by this paper
• Plasma Plasminogen Activator Inhibitor‐1 in Angina Pectoris: Influence of Plasma Insulin and Acute‐phase Response

  1989cited by this paper
• Increased Plasminogen Activator Inhibitor Activity in Non Insulin Dependent Diabetic Patients – Relationship with Plasma Insulin

  1989cited by this paper
• Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women.

  1989cited by this paper
• Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.

  1989cited by this paper
• Banting lecture 1988. Role of insulin resistance in human disease.

  1988cited by this paper
• Insulin Stimulates the Synthesis of Plasminogen Activator Inhibitor 1 by the Human Hepatocellular Cell Line Hep G2

  1988cited by this paper
• Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1.

  1987cited by this paper
• Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations.

  1987cited by this paper
• Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familial type 2 diabetes.

  1986cited by this paper
• The Fast-Acting Inhibitor of Tissue-Type Plasminogen Activator in Plasma Is also the Primary Plasma Inhibitor of Urokinase

  1986cited by this paper
• Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

  1985cited by this paper
• Nitrate therapy for ischaemic heart disease.

  1985cited by this paper

• Impaired ECM Remodeling and Macrophage Activity Define Necrosis and Regeneration Following Damage in Aged Skeletal Muscle

  2020cites this paper
• Alcohol Intoxication And The Post-Burn Gastrointestinal Hormonal Response.

  2019cites this paper
• Adiponectin—Consideration for its Role in Skeletal Muscle Health

  2019cites this paper
• The Efficacy of Pioglitazone Treatment in Myotonic Dystrophy Type 1 and Type 2 Diabetes Mellitus Patient

  2015cites this paper
• evaluating the impact of type 2 diabetes mellitus on cardiovascular risk in persons with metabolic syndrome using the UKPDS risk engine

  2015cites this paper
• Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus

  2015cites this paper
• Evaluating the impact of type 2 diabetes mellitus on cardiovascular risk in persons with metabolic syndrome using the UKPDS risk engine

  2015cites this paper
• Endothelial Function in Pre-diabetes, Diabetes and Diabetic Cardiomyopathy: A Review

  2014cites this paper
• Fibrinolytic factors in relation to anthropometry and incident type 2 diabetes.

  2014cites this paper
• Ocular and systemic markers for vascular function in those at risk of type 2 diabetes mellitus and cardiovascular disease

  2011cites this paper
• Comparison of Levels of Plasminogen Activator Inhibitor-1, Tissue Type Plasminogen Activator Antigen, Fibrinogen, and D- Dimer in Various Age Decades in Patients with Type-2 Diabetes Mellitus and Stable Coronary Artery Disease (From the BARI 2d Trial)

  2010cites this paper
• Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).

  2010cites this paper
• Association of Parental Obesity With Concentrations of Select Systemic Biomarkers in Nonobese Offspring

  2009cites this paper
• Chemokine and chemokine receptor gene expression in the mesenteric adipose tissue of KKAy mice.

  2009cites this paper
• Association of Parental Obesity with Concentrations of Select Systemic Biomarkers in Non-obese Offspring : The Framingham Heart Study

  2008cites this paper
• Influence of a family history of type II diabetes on fasting leptin and adiponectin plasma levels

  2008cites this paper
• Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors

  2008cites this paper
• Microcirculation and the Metabolic Syndrome

  2007cites this paper
• Fibrinolytic dysfunction after gestation is associated to components of insulin resistance and early type 2 diabetes in latino women with previous gestational diabetes.

  2007cites this paper
• Gender‐specific correlations of plasminogen activator inhibitor‐1 and tissue plasminogen activator levels with cardiovascular disease‐related traits

  2007cites this paper
• Plasma Levels of Asymmetric Dimethylarginine and Total Homocysteine in First Degree Relatives of Type 2 Diabetic Patients

  2007cites this paper
• Study of lipoprotein patterns as an atherogenic factor in T2DM patients and their FDRs.

  2007cites this paper
• Human visceral adipose tissue and the plasminogen activator inhibitor type 1

  2007cites this paper
• Adipocyte-derived hormones, cytokines, and mediators

  2006cites this paper
• The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders.

  2006cites this paper
• Plasminogen Activator Inhibitor-1 Deficiency Has Renal Benefits but Some Adverse Systemic Consequences in Diabetic Mice

  2006cites this paper
• Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: evidence for normal fibrinolytic state.

  2006cites this paper
• Plasminogen activator inhibitor-1 modulates adipocyte differentiation.

  2006cites this paper
• Cellular inflammatory responses: novel insights for obesity and insulin resistance.

  2006cites this paper
• Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation.

  2005cites this paper
• Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.

  2004cites this paper
• Inflammation, Insulin Resistance, and Atherosclerosis

  2004cites this paper
• Novel cardiovascular risk factors and macrovascular and microvascular complications of diabetes.

  2003cites this paper
• Effect of family history of type 2 diabetes on the intima-media thickness of the common carotid artery in normal-weight, overweight, and obese glucose-tolerant young adults.

  2003cites this paper
• Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis

  2003cites this paper
• Effect of metformin on fibrinolytic parameters in insulin-treated, type 2 diabetic patients.

  2003cites this paper
• Elevated plasma activator inhibitor 1 is not related to insulin resistance and to gene polymorphism in healthy centenarians.

  2002cites this paper
• Review: The genetics of macrovascular disease in diabetes

  2002cites this paper
• Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.

  2002cites this paper
• Prädiktive Untersuchungen bei phänotypisch gesunden Nachkommen von Patienten mit einem metabolischen Syndrom¹

  2001cites this paper
• [Predictive examinations of phenotypically healthy offspring of patients with a metabolic syndrome].

  2001cites this paper
• Increased plasma plasminogen activator inhibitor 1 in relatives of type 2 diabetic patients.

  2000cites this paper